0
Signin
countryflagCA

888-969-2592

RY 144.17 0.4529% TD 77.39 0.0517% SHOP 78.87 -1.3878% CNR 171.64 0.5625% ENB 50.09 -0.4769% CP 110.62 0.6277% BMO 128.85 -0.548% TRI 233.58 1.1563% CNQ 103.29 -0.174% BN 60.87 -0.2295% ATD 75.6 -1.447% CSU 3697.0 1.1582% BNS 65.76 -0.3485% CM 66.6 -0.5525% SU 54.21 1.1569% TRP 53.15 0.3398% NGT 58.54 -0.3405% WCN 226.5 0.4123% MFC 35.905 0.9986% BCE 46.75 -0.5954%

Fennec Pharmaceuticals Inc

Healthcare CA FRX

9.33CAD
-0.19(2.00%)

Last update at 2024-05-16T18:36:00Z

Day Range

9.139.33
LowHigh

52 Week Range

9.2715.43
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -23.71400M -17.34600M -18.10900M -12.77500M -9.88800M
Minority interest - - - - -
Net income -23.86100M -17.36500M -17.83100M -12.47700M -9.01900M
Selling general administrative 17.72M 12.24M 12.95M 7.40M 5.40M
Selling and marketing expenses 2.79M - - - -
Gross profit 1.45M - 0.17M - 0.00000M
Reconciled depreciation - 0.02M 0.40M 0.06M -
Ebit -22.58900M -17.22300M -17.88500M -12.77500M -10.40900M
Ebitda -22.54300M -17.18500M -17.98500M -13.00900M -10.57600M
Depreciation and amortization 0.05M 0.04M -0.10000M - -0.16700M
Non operating income net other - - - - -
Operating income -22.58900M -17.22300M -17.88500M -13.00900M -10.40900M
Other operating expenses 24.12M 17.22M 18.05M 13.01M 10.41M
Interest expense 0.98M 0.13M 0.00000M 0.00000M 0.35M
Tax provision - - - - -
Interest income 0.20M 0.12M 0.09M 0.25M 0.52M
Net interest income -0.93200M -0.07200M -0.31500M 0.25M 0.35M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.15M 0.02M -0.27800M -0.29800M -0.86900M
Total revenue 1.53M 0.00000M 0.17M 0.00000M 0.00000M
Total operating expenses 24.04M 17.22M 18.05M 13.01M 10.41M
Cost of revenue 0.09M - - - 0.00000M
Total other income expense net -1.12500M -0.12300M -0.22400M 0.23M 0.52M
Discontinued operations - - - - -
Net income from continuing ops -23.71400M -17.34600M -18.10900M -12.77500M -9.88800M
Net income applicable to common shares -23.71400M -17.34600M -18.10900M -12.77500M -9.88800M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 26.94M 22.41M 31.42M 14.15M 22.95M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.06M 0.25M 0.28M 0.23M 0.00100M
Total liab 29.51M 6.64M 2.35M 2.27M 1.64M
Total stockholder equity -2.56900M 15.77M 29.07M 11.88M 21.31M
Deferred long term liab 0.21M 0.03M - 0.26M -
Other current liab 2.22M 0.88M 0.78M 0.66M 0.60M
Common stock 142.59M 140.80M 140.73M 106.39M 106.39M
Capital stock 142.59M 140.80M 140.73M 106.39M 106.39M
Retained earnings -203.20000M -179.48600M -162.14000M -144.03100M -131.25600M
Other liab 0.26M 4.99M - - -
Good will - - - - -
Other assets 0.21M 0.03M 0.00000M 0.26M -
Cash 23.77M 21.10M 30.34M 13.65M 22.78M
Cash and equivalents 23.77M 21.10M 30.34M 13.65M 22.78M
Total current liabilities 4.61M 1.65M 2.35M 2.27M 1.64M
Current deferred revenue - - - - -
Net debt 1.12M -16.11200M -30.34400M -13.65000M -22.78100M
Short term debt 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Short long term debt - - - - -
Short long term debt total 24.90M 4.99M - - -
Other stockholder equity 56.80M 53.21M 49.23M 48.27M 44.93M
Property plant equipment - - - - -
Total current assets 26.73M 22.39M 31.42M 13.88M 22.95M
Long term investments - - - - -
Net tangible assets -2.56900M 15.77M 29.07M 11.88M 21.31M
Short term investments - - - - -
Net receivables 1.54M - - - -
Long term debt 24.90M 5.00M - - -
Inventory 0.58M - - - -
Accounts payable 2.39M 0.78M 1.57M 1.61M 1.03M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 1.24M 1.24M 1.24M 1.24M 1.24M
Additional paid in capital - - - - -
Common stock total equity - - 140.73M 106.39M 106.39M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 0.03M - 0.26M 0.00000M
Deferred long term asset charges - - - - -
Non current assets total 0.21M 0.03M 0.00000M 0.26M 0.00000M
Capital lease obligations - - - - -
Long term debt total 25.00M 5.00M 0.00000M 0.00000M 0.00000M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments - - - - 0.00000M
Change to liabilities 1.61M -0.79400M -0.04100M 0.58M 0.18M
Total cashflows from investing activities - - - - 0.00000M
Net borrowings 20.17M 4.99M 4.99M 4.99M 4.99M
Total cash from financing activities 20.73M 4.98M 32.29M -0.07100M 2.35M
Change to operating activities 1.61M -0.13800M -0.62200M -0.01100M -0.04500M
Net income -23.71400M -17.34600M -18.10900M -12.77500M -9.88800M
Change in cash 2.67M -9.24400M 16.69M -9.13100M -5.47900M
Begin period cash flow 21.10M 30.34M 13.65M 22.78M 28.26M
End period cash flow 23.77M 21.10M 30.34M 13.65M 22.78M
Total cash from operating activities -18.05800M -14.22200M -15.59500M -9.06000M -7.82600M
Issuance of capital stock - 0.00000M 31.97M - 0.00000M
Depreciation - 0.02M - - -
Other cashflows from investing activities - - - - 0.00000M
Dividends paid - - - - -
Change to inventory -0.57600M -0.57600M -0.57600M -0.57600M -
Change to account receivables -1.54500M -1.54500M -1.54500M -1.54500M -
Sale purchase of stock 0.93M 0.03M 32.29M -0.07100M 2.33M
Other cashflows from financing activities 25.73M 4.98M 0.32M -0.07100M 2.35M
Change to netincome 4.40M 4.04M 2.77M 3.08M 1.93M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 1.10M -0.93200M -0.76300M 0.57M 0.13M
Stock based compensation 4.09M 3.75M 2.79M 2.67M 1.82M
Other non cash items 0.47M 0.31M 0.49M 0.48M 0.10M
Free cash flow -18.05800M -14.22200M -15.59500M -9.06000M -7.82600M

Fundamentals

  • Previous Close 9.52
  • Market Cap379.81M
  • Volume4925
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-13.00900M
  • Revenue TTM13.05M
  • Revenue Per Share TTM0.49
  • Gross Profit TTM 1.45M
  • Diluted EPS TTM-1.01

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
FRX
Fennec Pharmaceuticals Inc		 -0.19 2.00% 9.33 - 33.33 29.10 84.57 30.47 -23.3985
SVA
Sernova Corp		 -0.025 7.14% 0.33 - - - 7.95 -4.4095
EPRX
Eupraxia Pharmaceuticals Inc		 -0.01 0.25% 4.00 - - - 8.40 -3.9163
TH
Theratechnologies Inc.		 0.01 0.56% 1.81 - 55.25 1.64 19.46 2.23 -11.7353
ONC
Oncolytics Biotech Inc		 -0.01 0.64% 1.56 - - - 4.00 -2.3144

Reports Covered

Stock Research & News

View All

Profile

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. The company's product candidates include PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity hearing loss in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Fennec Pharmaceuticals Inc

68 TW Alexander Drive, Research Triangle Park, NC, United States, 27709

Key Executives

Name Title Year Born
Mr. Rostislav Raykov CEO & Director 1976
Mr. Robert C. Andrade Chief Financial Officer 1975
Mr. Mark Meier Sr. VP of Commercial NA
Mr. Mark Gowland Controller NA
Mr. Lei Fang Pres of Pharstat Inc NA
Ms. Anne McKay Regulatory Consultant 1954
Mr. Alexander D. Smith M.S. Consultant NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).